BRAF and melanoma: Thus, RND3‐RhoA signaling presents a possible compensatory mechanism in wild‐type BRAF and BRAFV600‐mutant melanoma cells treated with a BRAF inhibitor, suggesting that it could be a potential drug target in combination with WNT5A interference.